PROPOSED: Every newly diagnosed person with pancreatic cancer (ductal adenocarcinoma of the pancreas) should receive genetic screening prior to beginning treatment – to test for germline genetic mutations in the homologous recombination DNA repair pathway, including genes such as BRCA1, BRCA2, PALB2, and others. These results, in from 12% to 17% of pancreatic cancer patients, suggest that treatment that includes DNA cross-linking agents such as compounds or PARP inhibitors may be superior to standard best practices therapy.
OFFER: Color Genomics offers a 30-gene cancer panel for $224 (normally $249) when the Promotion Code “PANCREATIC” is entered at checkout (price will reduce upon entering this code). This is a physician-ordered saliva kit. Click Here for more information
RATIONALE: The age of precision medicine in pancreatic cancer is approaching … [MORE]
Our Philosophy About Pancreatic Cancer
Pancreatic cancer is a serious disease. Taking an aggressive rational stance against pancreas cancer, at the earliest possible time, supported by the best medical team, and treated in the most appropriate manner gives the best chance for pancreatic cancer survival. We believe in strong patient-physician bonds, scientifically-based pancreatic cancer treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done. That the best approach is meeting cancer of the pancreas head-on and armed with the best available information.
Recently, a seasoned specialist told us that we had the highest social good to donation ratio that they had ever seen in any non-profit. We put all donations to serious use toward the mission of fighting pancreatic cancer. Less than 8% of donated funds are used for management expenses.
Speak with a Survivor:
Call 1-800-433-0464 for a free service that will place you in contact with a fellow survivor, or to volunteer to contact someone more recently diagnosed.